Phase 1, Open-label, Dose Escalation Study of Milademetan, an Oral MDM2 Inhibitor, to Assess Safety, Tolerability and Pharmacokinetics in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Milademetan (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 28 Oct 2019 Status changed from active, no longer recruiting to completed.
- 21 Aug 2019 Planned End Date changed from 30 Jun 2019 to 30 Nov 2019.
- 21 Aug 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Nov 2019.